MUBRITINIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H23F3N4O2
Molecular Weight	468.4709
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1

InChI

InChIKey=ZTFBIUXIQYRUNT-MDWZMJQESA-N

InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

HIDE SMILES / InChI

Molecular Formula	C25H23F3N4O2
Molecular Weight	468.4709
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.medchemexpress.com/product_pdf/HY-13501/Mubritinib-DataSheet.pdf
Curator's Comment: description was created based on several sources, including: http://www.hoelzel-biotech.com/media/import/pdf_manual/Selleckchem//S2216-10__Manual.pdf https://www.ncbi.nlm.nih.gov/pubmed/16771730 http://adisinsight.springer.com/drugs/800019257

TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Mubritinib displays > 4000-fold selectivity over other tyrosine kinases, such as EGFR, FGFR, PDGFR, Jak1, Src and Blk. A Phase I study to investigate a safe dose of Mubritinib, once daily (QD), in patients with tumors known to express HER2 (Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm) has been completed, but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Receptor protein-tyrosine kinase erbB-2 35 Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16771730	Inhibitor 8504		6.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://clinicaltrials.gov/ct2/show/NCT00034281 http://adisinsight.springer.com/drugs/800019257	Primary		Phase I 438	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00799W	https://www.1pchem.com/search?query=1P00799W
AK Scientific	SYN1112	https://aksci.com/item_detail.php?cat=SYN1112
AK Scientific	X7505	https://aksci.com/item_detail.php?cat=X7505
AOBIOUS INC	AOB6507	http://aobious.com/aobious/search?search_query=AOB6507
AstaTech	41131	http://astatechinc.com/CPSResult.php?CRNO=41131
AstaTech	41326	http://astatechinc.com/CPSResult.php?CRNO=41326
Axon MedChem	2053	https://www.axonmedchem.com/product/2053
BLD Pharm	BD140529	http://www.bldpharm.com/search/Search.html?keyword=BD140529
BLD Pharm	BD435582	http://www.bldpharm.com/search/Search.html?keyword=BD435582
BOC Sciences	366017-09-6	http://www.bocsci.com/description.asp?cas=366017-09-6
Cayman Chemical	12096	http://www.caymanchem.com/app/template/Product.vm/catalog/12096
Chem Scene	CS-3954	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3954
ChemShuttle	109790	https://www.chemshuttle.com/catalogsearch/result/?q=109790
eMolecules	176929084	https://orderbb.emolecules.com/search/#?query=176929084
eMolecules	29703216	https://orderbb.emolecules.com/search/#?query=29703216
eMolecules	44842441	https://orderbb.emolecules.com/search/#?query=44842441
eMolecules	53927080	https://orderbb.emolecules.com/search/#?query=53927080
eNovation Chemicals	D372539	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372539&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A2107	http://www.excenen.com/searchresultlist.php?id=EX-A2107
Hairui	HR114919	http://www.hairuichem.com/en/product/search.do?q=HR114919
KeyOrganics	AS-16256	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16256
Lab Seeker	SC-23332	http://www.labseeker.com/search.php?keywords=SC-23332&category=0
LabSeeker	SC-23332	http://www.labseeker.com/search.php?keywords=SC-23332&category=0
Matrix Scientific	146683	http://www.matrixscientific.com/146683.html
mcule	MCULE-3759134837	https://mcule.com/MCULE-3759134837/
mcule	MCULE-9808178203	https://mcule.com/MCULE-9808178203/
MedChem Express	HY-13501	https://www.medchemexpress.com/search.html?q=HY-13501&ft=&fa=&fp=
Molnova	M18478	https://www.molnova.com/en/serch-list.html?keywords=M18478
MolPort	MolPort-008-155-960	https://www.molport.com/shop/molecule-link/MolPort-008-155-960
MuseChem	I003349	https://www.musechem.com/product/I003349.html
Ryan Scientific	101-94038	https://ryansci.com/products?q=101-94038&list_q=&search_type=exact
Selleck Chemicals	S2216	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2216
ShangHai Biochempartner	BCP02837	http://www.biochempartner.com/search_BCP02837
TargetMol	T6124	https://www.targetmol.com/search?keyword=T6124
Tetrahedron	TS82734	http://www.thsci.com/search.do?q=TS82734
Tocris	3599	https://www.tocris.com/search.php?Type=QuickSearch&Value=3599
Toronto Research Chemicals	M790785	https://www.trc-canada.com/product-detail/?CatNum=M790785

PubMed

Title	Date	PubMed
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	2013-04-15	23398362
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	2011-10-30	22037377
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.	2006-05	16771730

Patents

Sample Use Guides

In Vivo Use Guide

Starting dose of TAK-165 10 mg, tablets, once daily with dose escalation to tolerability for 56 days.

Route of Administration: Oral

In Vitro Use Guide

To evaluate TAK-165 sensitivity in vitro, after cells weretreated with TAK-165 at various concentrations continu-ously for 3 days. TAK-165 sensitivity depends on HER2 levels of each cellline. Especially, BT474 cells which over-express HER2strongly was highly sensitive (IC50 0.005 µmol/L) and PC-3 cells which express HER2 very weakly was less sensitive(IC50 4.62 µmol/L). But, HT1376 and ACHN cells thatover-expressed EGFR showed high IC50 (IC50 > 25 µmol/L).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:12 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:12 GMT 2025`
Record UNII	V734AZP9BR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAK-165

Preferred Name

English

MUBRITINIB

Official Name

English

mubritinib [INN]

Common Name

English

1-[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole

Systematic Name

English

1H-1,2,3-TRIAZOLE, 1-(4-(4-((2-((1E)-2-(4-(TRIFLUOROMETHYL)PHENYL)ETHENYL)-4-OXAZOLYL)METHOXY)PHENYL)BUTYL)-

Systematic Name

English

MUBRITINIB [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2167